Low maternal concentrations of soluble vascular endothelial growth factor receptor-2 in preeclampsia and small for gestational age

References

• Redman C W, Sargent I L. Latest advances in understanding preeclampsia. Science 2005; 308: 1592–1594
   PubMed Web of Science ®Google Scholar
• Roberts J M, Gammill H S. Preeclampsia: Recent insights. Hypertension 2005; 46: 1243–1249
   PubMed Web of Science ®Google Scholar
• Romero R, Lockwood C, Oyarzun E, Hobbins J C. Toxemia: New concepts in an old disease. Semin Perinatol 1988; 12: 302–323
   PubMed Web of Science ®Google Scholar
• Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005; 365: 785–799
   PubMed Web of Science ®Google Scholar
• Robertson W B, Brosens I, Dixon G. Maternal uterine vascular lesions in the hypertensive complications of pregnancy. Perspect Nephrol Hypertens 1976; 5: 115–127
   PubMedGoogle Scholar
• Brosens I A. Morphological changes in the utero-placental bed in pregnancy hypertension. Clin Obstet Gynaecol 1977; 4: 573–593
   PubMed Web of Science ®Google Scholar
• Sheppard B L, Bonnar J. An ultrastructural study of utero-placental spiral arteries in hypertensive and normotensive pregnancy and fetal growth retardation. Br J Obstet Gynaecol 1981; 88: 695–705
   PubMedGoogle Scholar
• Khong T Y, De Wolf F, Robertson W B, Brosens I. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol 1986; 93: 1049–1059
   PubMedGoogle Scholar
• Pijnenborg R, Anthony J, Davey D A, Rees A, Tiltman A, Vercruysse L, van Assche A. Placental bed spiral arteries in the hypertensive disorders of pregnancy. Br J Obstet Gynaecol 1991; 98: 648–655
   PubMedGoogle Scholar
• Kaufmann P, Black S, Huppertz B. Endovascular trophoblast invasion: Implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol Reprod 2003; 69: 1–7
   PubMed Web of Science ®Google Scholar
• Fisher S J. The placental problem: Linking abnormal cytotrophoblast differentiation to the maternal symptoms of preeclampsia. Reprod Biol Endocrinol 2004; 2: 53
   PubMedGoogle Scholar
• Johansen M, Redman C W, Wilkins T, Sargent I L. Trophoblast deportation in human pregnancy—its relevance for pre-eclampsia. Placenta 1999; 20: 531–539
   PubMed Web of Science ®Google Scholar
• Redman C W, Sargent I L. Placental debris, oxidative stress and pre-eclampsia. Placenta 2000; 21: 597–602
   PubMed Web of Science ®Google Scholar
• Sargent I L, Germain S J, Sacks G P, Kumar S, Redman C W. Trophoblast deportation and the maternal inflammatory response in pre-eclampsia. J Reprod Immunol 2003; 59: 153–160
   PubMed Web of Science ®Google Scholar
• Huppertz B, Kingdom J, Caniggia I, Desoye G, Black S, Korr H, Kaufmann P. Hypoxia favours necrotic versus apoptotic shedding of placental syncytiotrophoblast into the maternal circulation. Placenta 2003; 24: 181–190
   PubMed Web of Science ®Google Scholar
• Mor G, Gutierrez L S, Eliza M, Kahyaoglu F, Arici A. Fas–fas ligand system-induced apoptosis in human placenta and gestational trophoblastic disease. Am J Reprod Immunol 1998; 40: 89–94
   PubMed Web of Science ®Google Scholar
• Neale D, Demasio K, Illuzi J, Chaiworapongsa T, Romero R, Mor G. Maternal serum of women with pre-eclampsia reduces trophoblast cell viability: Evidence for an increased sensitivity to Fas-mediated apoptosis. J Matern Fetal Neonatal Med 2003; 13: 39–44
   PubMedGoogle Scholar
• Chappell L C, Seed P T, Briley A, Kelly F J, Hunt B J, Charnock-Jones D S, Mallet A I, Poston L. A longitudinal study of biochemical variables in women at risk of preeclampsia. Am J Obstet Gynecol 2002; 187: 127–136
   PubMed Web of Science ®Google Scholar
• Hubel C A. Oxidative stress in the pathogenesis of preeclampsia. Proc Soc Exp Biol Med 1999; 222: 222–235
   PubMed Web of Science ®Google Scholar
• Bowen R S, Moodley J, Dutton M F, Theron A J. Oxidative stress in pre-eclampsia. Acta Obstet Gynecol Scand 2001; 80: 719–725
   PubMed Web of Science ®Google Scholar
• Walsh S W. Maternal–placental interactions of oxidative stress and antioxidants in preeclampsia. Semin Reprod Endocrinol 1998; 16: 93–104
   PubMedGoogle Scholar
• Rogers M S, Wang C C, Tam W H, Li C Y, Chu K O, Chu C Y. Oxidative stress in midpregnancy as a predictor of gestational hypertension and pre-eclampsia. BJOG 2006; 113: 1053–1059
   PubMed Web of Science ®Google Scholar
• Chamy V M, Lepe J, Catalan A, Retamal D, Escobar J A, Madrid E M. Oxidative stress is closely related to clinical severity of pre-eclampsia. Biol Res 2006; 39: 229–236
   PubMed Web of Science ®Google Scholar
• Sharma J B, Sharma A, Bahadur A, Vimala N, Satyam A, Mittal S. Oxidative stress markers and antioxidant levels in normal pregnancy and pre-eclampsia. Int J Gynaecol Obstet 2006; 94: 23–27
   PubMed Web of Science ®Google Scholar
• Burton G J, Jauniaux E. Placental oxidative stress: From miscarriage to preeclampsia. J Soc Gynecol Investig 2004; 11: 342–352
   PubMedGoogle Scholar
• Roberts J M, Hubel C A. Oxidative stress in preeclampsia. Am J Obstet Gynecol 2004; 190: 1177–1178
   PubMed Web of Science ®Google Scholar
• Wiktor H, Kankofer M, Schmerold I, Dadak A, Lopucki M, Niedermuller H. Oxidative DNA damage in placentas from normal and pre-eclamptic pregnancies. Virchows Arch 2004; 445: 74–78
   PubMed Web of Science ®Google Scholar
• Gervasi M T, Chaiworapongsa T, Pacora P, Naccasha N, Yoon B H, Maymon E, Romero R. Phenotypic and metabolic characteristics of monocytes and granulocytes in preeclampsia. Am J Obstet Gynecol 2001; 185: 792–797
   PubMed Web of Science ®Google Scholar
• Redman C W, Sacks G P, Sargent I L. Preeclampsia: An excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999; 180: 499–506
   PubMed Web of Science ®Google Scholar
• Sacks G P, Studena K, Sargent K, Redman C W. Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. Am J Obstet Gynecol 1998; 179: 80–86
   PubMed Web of Science ®Google Scholar
• Seely E W, Solomon C G. Insulin resistance and its potential role in pregnancy-induced hypertension. J Clin Endocrinol Metab 2003; 88: 2393–2398
   PubMed Web of Science ®Google Scholar
• Wolf M, Sandler L, Munoz K, Hsu K, Ecker J L, Thadhani R. First trimester insulin resistance and subsequent preeclampsia: A prospective study. J Clin Endocrinol Metab 2002; 87: 1563–1568
   PubMed Web of Science ®Google Scholar
• Thadhani R, Ecker J L, Mutter W P, Wolf M, Smirnakis K V, Sukhatme V P, Levine R J, Karumanchi S A. Insulin resistance and alterations in angiogenesis: Additive insults that may lead to preeclampsia. Hypertension 2004; 43: 988–992
   PubMed Web of Science ®Google Scholar
• Innes K E, Weitzel L, Laudenslager M. Altered metabolic profiles among older mothers with a history of preeclampsia. Gynecol Obstet Invest 2005; 59: 192–201
   PubMedGoogle Scholar
• Enquobahrie D A, Williams M A, Butler C L, Frederick I O, Miller R S, Luthy D A. Maternal plasma lipid concentrations in early pregnancy and risk of preeclampsia. Am J Hypertens 2004; 17: 574–581
   PubMed Web of Science ®Google Scholar
• Clausen T, Djurovic S, Henriksen T. Dyslipidemia in early second trimester is mainly a feature of women with early onset pre-eclampsia. BJOG 2001; 108: 1081–1087
   PubMed Web of Science ®Google Scholar
• Hubel C A, Lyall F, Weissfeld L, Gandley R E, Roberts J M. Small low-density lipoproteins and vascular cell adhesion molecule-1 are increased in association with hyperlipidemia in preeclampsia. Metabolism 1998; 47: 1281–1288
   PubMed Web of Science ®Google Scholar
• Weiner C P, Kwaan H C, Xu C, Paul M, Burmeister L, Hauck W. Antithrombin III activity in women with hypertension during pregnancy. Obstet Gynecol 1985; 65: 301–306
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Yoshimatsu J, Espinoza J, Kim Y M, Berman S, Edwin S, Yoon B H, Romero R. Evidence of in vivo generation of thrombin in patients with small-for-gestational-age fetuses and pre-eclampsia. J Matern Fetal Neonatal Med 2002; 11: 362–367
   PubMedGoogle Scholar
• Cadroy Y, Grandjean H, Pichon J, Desprats R, Berrebi A, Fournie A, Boneu B. Evaluation of six markers of haemostatic system in normal pregnancy and pregnancy complicated by hypertension or pre-eclampsia. Br J Obstet Gynaecol 1993; 100: 416–420
   PubMedGoogle Scholar
• Hayashi M, Inoue T, Hoshimoto K, Negishi H, Ohkura T, Inaba N. Characterization of five marker levels of the hemostatic system and endothelial status in normotensive pregnancy and pre-eclampsia. Eur J Haematol 2002; 69: 297–302
   PubMed Web of Science ®Google Scholar
• de Boer K, ten Cate J W, Sturk A, Borm J J, Treffers P E. Enhanced thrombin generation in normal and hypertensive pregnancy. Am J Obstet Gynecol 1989; 160: 95–100
   PubMed Web of Science ®Google Scholar
• Higgins J R, Walshe J J, Darling M R, Norris L, Bonnar J. Hemostasis in the uteroplacental and peripheral circulations in normotensive and pre-eclamptic pregnancies. Am J Obstet Gynecol 1998; 179: 520–526
   PubMed Web of Science ®Google Scholar
• Friedman S A, Schiff E, Emeis J J, Dekker G A, Sibai B M. Biochemical corroboration of endothelial involvement in severe preeclampsia. Am J Obstet Gynecol 1995; 172: 202–203
   PubMed Web of Science ®Google Scholar
• Roberts J M, Taylor R N, Goldfien A. Endothelial cell activation as a pathogenetic factor in preeclampsia. Semin Perinatol 1991; 15: 86–93
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Yoshimatsu J, Espinoza J, Kim Y M, Park K, Kalache K, Edwin S, Bujold E, Gomez R. Soluble adhesion molecule profile in normal pregnancy and pre-eclampsia. J Matern Fetal Neonatal Med 2002; 12: 19–27
   PubMedGoogle Scholar
• Odegard R A, Vatten L J, Nilsen S T, Salvesen K A, Austgulen R. Preeclampsia and fetal growth. Obstet Gynecol 2000; 96: 950–955
   PubMed Web of Science ®Google Scholar
• Xiao R, Sorensen T K, Williams M A, Luthy D A. Influence of pre-eclampsia on fetal growth. J Matern Fetal Neonatal Med 2003; 13: 157–162
   PubMedGoogle Scholar
• Romero R. Prenatal medicine: The child is the father of the man. Prenat Neonatal Med 1996; 1: 8–11
   Google Scholar
• Seeds J W. Impaired fetal growth: Definition and clinical diagnosis. Obstet Gynecol 1984; 64: 303–310
   PubMed Web of Science ®Google Scholar
• Wulff C, Wilson H, Dickson S E, Wiegand S J, Fraser H M. Hemochorial placentation in the primate: Expression of vascular endothelial growth factor, angiopoietins, and their receptors throughout pregnancy. Biol Reprod 2002; 66: 802–812
   PubMed Web of Science ®Google Scholar
• Fisher S, Genbacev O, Maidji E, Pereira L. Human cytomegalovirus infection of placental cytotrophoblasts in vitro and in utero: Implications for transmission and pathogenesis. J Virol 2000; 74: 6808–6820
   PubMed Web of Science ®Google Scholar
• Arechavaleta-Velasco F, Koi H, Strauss J F, III, Parry S. Viral infection of the trophoblast: Time to take a serious look at its role in abnormal implantation and placentation?. J Reprod Immunol 2002; 55: 113–121
   PubMed Web of Science ®Google Scholar
• Snijders R J, Sherrod C, Gosden C M, Nicolaides K H. Fetal growth retardation: Associated malformations and chromosomal abnormalities. Am J Obstet Gynecol 1993; 168: 547–555
   PubMed Web of Science ®Google Scholar
• den Hollander N S, Cohen-Overbeek T E, Heydanus R, Stewart P A, Brandenburg H, Los F L, Jahoda M G, Wladimiroff J W. Cordocentesis for rapid karyotyping in fetuses with congenital anomalies or severe IUGR. Eur J Obstet Gynecol Reprod Biol 1994; 53: 183–187
   PubMedGoogle Scholar
• Kupferminc M J, Many A, Bar-Am A, Lessing J B, Ascher-Landsberg J. Mid-trimester severe intrauterine growth restriction is associated with a high prevalence of thrombophilia. BJOG 2002; 109: 1373–1376
   PubMed Web of Science ®Google Scholar
• Constancia M, Hemberger M, Hughes J, Dean W, Ferguson-Smith A, Fundele R, Stewart F, Kelsey G, Fowden A, Sibley C, et al. Placental-specific IGF-II is a major modulator of placental and fetal growth. Nature 2002; 417: 945–948
   PubMed Web of Science ®Google Scholar
• Ghezzi F, Tibiletti M G, Raio L, Di Naro E, Lischetti B, Taborelli M, Franchi M. Idiopathic fetal intrauterine growth restriction: A possible inheritance pattern. Prenat Diagn 2003; 23: 259–264
   PubMed Web of Science ®Google Scholar
• Prada J A, Tsang R C. Biological mechanisms of environmentally induced causes of IUGR. Eur J Clin Nutr 1998; 52(Suppl 1)S21–27
   Google Scholar
• Andres R L, Day M C. Perinatal complications associated with maternal tobacco use. Semin Neonatol 2000; 5: 231–241
   PubMedGoogle Scholar
• Misra D P, Nguyen R H. Environmental tobacco smoke and low birth weight: A hazard in the workplace?. Environ Health Perspect 1999; 107(Suppl 6)897–904
   PubMedGoogle Scholar
• Kuzma J W, Sokol R J. Maternal drinking behavior and decreased intrauterine growth. Alcohol Clin Exp Res 1982; 6: 396–402
   PubMedGoogle Scholar
• Bada H S, Das A, Bauer C R, Shankaran S, Lester B, Wright L L, Verter J, Smeriglio V L, Finnegan L P, Maza P L. Gestational cocaine exposure and intrauterine growth: Maternal lifestyle study. Obstet Gynecol 2002; 100: 916–924
   PubMed Web of Science ®Google Scholar
• Sabatier F, Bretelle F, D'Ercole C, Boubli L, Sampol J, Dignat-George F. Neutrophil activation in preeclampsia and isolated intrauterine growth restriction. Am J Obstet Gynecol 2000; 183: 1558–1563
   PubMed Web of Science ®Google Scholar
• Friedman S A, de Groot C J, Taylor R N, Golditch B D, Roberts J M. Plasma cellular fibronectin as a measure of endothelial involvement in preeclampsia and intrauterine growth retardation. Am J Obstet Gynecol 1994; 170: 838–841
   PubMed Web of Science ®Google Scholar
• Bretelle F, Sabatier F, Blann A, D'Ercole C, Boutiere B, Mutin M, Boubli L, Sampol J, Dignat-George F. Maternal endothelial soluble cell adhesion molecules with isolated small for gestational age fetuses: Comparison with pre-eclampsia. BJOG 2001; 108: 1277–1282
   PubMed Web of Science ®Google Scholar
• Johnson M R, Anim-Nyame N, Johnson P, Sooranna S R, Steer P J. Does endothelial cell activation occur with intrauterine growth restriction?. BJOG 2002; 109: 836–839
   PubMed Web of Science ®Google Scholar
• Ray J G, Vermeulen M J, Schull M J, Redelmeier D A. Cardiovascular health after maternal placental syndromes (CHAMPS): Population-based retrospective cohort study. Lancet 2005; 366: 1797–1803
   PubMed Web of Science ®Google Scholar
• Sattar N. Do pregnancy complications and CVD share common antecedents?. Atheroscler Suppl 2004; 5: 3–7
   PubMed Web of Science ®Google Scholar
• Jonsdottir L S, Arngrimsson R, Geirsson R T, Sigvaldason H, Sigfusson N. Death rates from ischemic heart disease in women with a history of hypertension in pregnancy. Acta Obstet Gynecol Scand 1995; 74: 772–776
   PubMed Web of Science ®Google Scholar
• Davey S G, Hart C, Ferrell C, Upton M, Hole D, Hawthorne V, Watt G. Birth weight of offspring and mortality in the Renfrew and Paisley study: Prospective observational study. BMJ 1997; 315: 1189–1193
   PubMedGoogle Scholar
• Smith G D, Sterne J, Tynelius P, Lawlor D A, Rasmussen F. Birth weight of offspring and subsequent cardiovascular mortality of the parents. Epidemiology 2005; 16: 563–569
   PubMedGoogle Scholar
• Lawlor D A, Davey S G, Whincup P, Wannamethee G, Papacosta O, Dhanjil S, Griffin M, Nicolaides A N, Ebrahim S. Association between offspring birth weight and atherosclerosis in middle aged men and women: British Regional Heart Study. J Epidemiol Community Health 2003; 57: 462–463
   PubMedGoogle Scholar
• Wolf M, Hubel C A, Lam C, Sampson M, Ecker J L, Ness R B, Rajakumar A, Daftary A, Shakir A S, Seely E W, et al. Preeclampsia and future cardiovascular disease: Potential role of altered angiogenesis and insulin resistance. J Clin Endocrinol Metab 2004; 89: 6239–6243
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber H P, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669–676
   PubMed Web of Science ®Google Scholar
• Wulff C, Weigand M, Kreienberg R, Fraser H M. Angiogenesis during primate placentation in health and disease. Reproduction 2003; 126: 569–577
   PubMed Web of Science ®Google Scholar
• Smith S K, He Y, Clark D E, Charnock-Jones D S. Angiogenic growth factor expression in placenta. Semin Perinatol 2000; 24: 82–86
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380: 435–439
   PubMed Web of Science ®Google Scholar
• Fong G H, Rossant J, Gertsenstein M, Breitman M L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 376: 66–70
   PubMed Web of Science ®Google Scholar
• Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea K S, Powell-Braxton L, Hillan K J, Moore M W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380: 439–442
   PubMed Web of Science ®Google Scholar
• Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 2006; 39: 469–478
   PubMedGoogle Scholar
• Sane D C, Anton L, Brosnihan K B. Angiogenic growth factors and hypertension. Angiogenesis 2004; 7: 193–201
   PubMedGoogle Scholar
• Gerber H P, McMurtrey A, Kowalski J, Yan M, Keyt B A, Dixit V, Ferrara N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998; 273: 30 336–30 343
   Google Scholar
• Maynard S E, Min J Y, Merchan J, Lim K H, Li J, Mondal S, Libermann T A, Morgan J P, Sellke F W, Stillman I E, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649–658
   PubMed Web of Science ®Google Scholar
• Luttun A, Carmeliet P. Soluble VEGF receptor Flt1: The elusive preeclampsia factor discovered?. J Clin Invest 2003; 111: 600–602
   PubMed Web of Science ®Google Scholar
• Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim Y M, Bdolah Y, Lim K H, Yuan H T, Libermann T A, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12: 642–649
   PubMed Web of Science ®Google Scholar
• Levine R J, Maynard S E, Qian C, Lim K H, England L J, Yu K F, Schisterman E F, Thadhani R, Sachs B P, Epstein F H, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672–683
   PubMed Web of Science ®Google Scholar
• Hertig A, Berkane N, Lefevre G, Toumi K, Marti H P, Capeau J, Uzan S, Rondeau E. Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. Clin Chem 2004; 50: 1702–1703
   PubMed Web of Science ®Google Scholar
• McKeeman G C, Ardill J E, Caldwell C M, Hunter A J, McClure N. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol 2004; 191: 1240–1246
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Kim Y M, Kim G J, Kim M R, Espinoza J, Bujold E, Goncalves L, Gomez R, Edwin S, et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005; 17: 3–18
   PubMed Web of Science ®Google Scholar
• Park C W, Park J S, Shim S S, Jun J K, Yoon B H, Romero R. An elevated maternal plasma, but not amniotic fluid, soluble fms-like tyrosine kinase-1 (sFlt-1) at the time of mid-trimester genetic amniocentesis is a risk factor for preeclampsia. Am J Obstet Gynecol 2005; 193: 984–989
   PubMed Web of Science ®Google Scholar
• Powers R W, Roberts J M, Cooper K M, Gallaher M J, Frank M P, Harger G F, Ness R B. Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia. Am J Obstet Gynecol 2005; 193: 185–191
   PubMed Web of Science ®Google Scholar
• Wathen K A, Tuutti E, Stenman U H, Alfthan H, Halmesmaki E, Finne P, Ylikorkala O, Vuorela P. Maternal serum soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in pre-eclampsia or intrauterine growth retardation. J Clin Endocrinol Metab 2006; 91: 180–184
   PubMed Web of Science ®Google Scholar
• Parra M, Rodrigo R, Barja P, Bosco C, Fernandez V, Munoz H, Soto-Chacon E. Screening test for preeclampsia through assessment of uteroplacental blood flow and biochemical markers of oxidative stress and endothelial dysfunction. Am J Obstet Gynecol 2005; 193: 1486–1491
   PubMed Web of Science ®Google Scholar
• Koga K, Osuga Y, Yoshino O, Hirota Y, Ruimeng X, Hirata T, Takeda S, Yano T, Tsutsumi O, Taketani Y. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 2003; 88: 2348–2351
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Espinoza J, Bujold E, Mee K Y, Goncalves L F, Gomez R, Edwin S. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol 2004; 190: 1541–1547
   PubMed Web of Science ®Google Scholar
• Stepan H, Geide A, Faber R. Soluble fms-like tyrosine kinase 1. N Engl J Med 2004; 351: 2241–2242
   PubMed Web of Science ®Google Scholar
• Staff A C, Braekke K, Harsem N K, Lyberg T, Holthe M R. Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 2005; 122: 33–39
   PubMed Web of Science ®Google Scholar
• Tsatsaris V, Goffin F, Munaut C, Brichant J F, Pignon M R, Noel A, Schaaps J P, Cabrol D, Frankenne F, Foidart J M. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: Pathophysiological consequences. J Clin Endocrinol Metab 2003; 88: 5555–5563
   PubMed Web of Science ®Google Scholar
• Shibata E, Rajakumar A, Powers R W, Larkin R W, Gilmour C, Bodnar L M, Crombleholme W R, Ness R B, Roberts J M, Hubel C A. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: Relationship to circulating placental growth factor. J Clin Endocrinol Metab 2005; 90: 4895–4903
   PubMed Web of Science ®Google Scholar
• Ebos J M, Bocci G, Man S, Thorpe P E, Hicklin D J, Zhou D, Jia X, Kerbel R S. A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol Cancer Res 2004; 2: 315–326
   PubMed Web of Science ®Google Scholar
• Agostini H, Boden K, Unsold A, Martin G, Hansen L, Fiedler U, Esser N, Marme D. A single local injection of recombinant VEGF receptor 2 but not of Tie2 inhibits retinal neovascularization in the mouse. Curr Eye Res 2005; 30: 249–257
   PubMed Web of Science ®Google Scholar
• Robak E, Sysa-Jedrzejewska A, Robak T. Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus. Mediators Inflamm 2003; 12: 293–298
   PubMedGoogle Scholar
• Wierzbowska A, Robak T, Wrzesien-Kus A, Krawczynska A, Lech-Maranda E, Urbanska-Rys H. Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia. Eur Cytokine Netw 2003; 14: 149–153
   PubMed Web of Science ®Google Scholar
• Masuyama H, Suwaki N, Nakatsukasa H, Masumoto A, Tateishi Y, Hiramatsu Y. Circulating angiogenic factors in preeclampsia, gestational proteinuria, and preeclampsia superimposed on chronic glomerulonephritis. Am J Obstet Gynecol 2006; 194: 551–556
   PubMed Web of Science ®Google Scholar
• Alexander G R, Himes J H, Kaufman R B, Mor J, Kogan M. A United States national reference for fetal growth. Obstet Gynecol 1996; 87: 163–168
   PubMed Web of Science ®Google Scholar
• Sibai B M, Ewell M, Levine R J, Klebanoff M A, Esterlitz J, Catalano P M, Goldenberg R L, Joffe G. Risk factors associated with preeclampsia in healthy nulliparous women. The Calcium for Preeclampsia Prevention (CPEP) Study Group. Am J Obstet Gynecol 1997; 177: 1003–1010
   PubMed Web of Science ®Google Scholar
• Harrington K F, Campbell S, Bewley S, Bower S. Doppler velocimetry studies of the uterine artery in the early prediction of pre-eclampsia and intra-uterine growth retardation. Eur J Obstet Gynecol Reprod Biol 1991; 42(Suppl)S14–20
   PubMed Web of Science ®Google Scholar
• Kurmanavicius J, Florio I, Wisser J, Hebisch G, Zimmermann R, Muller R, Huch R, Huch A. Reference resistance indices of the umbilical, fetal middle cerebral and uterine arteries at 24–42 weeks of gestation. Ultrasound Obstet Gynecol 1997; 10: 112–120
   PubMed Web of Science ®Google Scholar
• Bower S, Schuchter K, Campbell S. Doppler ultrasound screening as part of routine antenatal scanning: Prediction of pre-eclampsia and intrauterine growth retardation. Br J Obstet Gynaecol 1993; 100: 989–994
   PubMedGoogle Scholar
• Taylor R N, Grimwood J, Taylor R S, McMaster M T, Fisher S J, North R A. Longitudinal serum concentrations of placental growth factor: Evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 2003; 188: 177–182
   PubMed Web of Science ®Google Scholar
• Tidwell S C, Ho H N, Chiu W H, Torry R J, Torry D S. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol 2001; 184: 1267–1272
   PubMed Web of Science ®Google Scholar
• Krauss T, Pauer H U, Augustin H G. Prospective analysis of placenta growth factor (PlGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia. Hypertens Pregnancy 2004; 23: 101–111
   PubMed Web of Science ®Google Scholar
• Schlembach D, Beinder E. Angiogenic factors in preeclampsia. J Soc Gynecol Investig 2003; 10: 316A
   Google Scholar
• Kim S Y, Park S Y, Kim J W, Kim Y M, Yang J H, Kim M Y, Ahn H K, Shin J S, Kim J O, Ryu H M. Circulating endothelial progenitor cells, plasma VEGF, VEGFR-1 and VEGFR-2 levels in preeclampsia. Am J Obstet Gynecol 2005; 193: S74
   Google Scholar
• Wallner W, Sengenberger R, Strick R, Strissel P L, Meurer B, Beckmann M W, Schlembach D. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin Sci (Lond) 2007; 112: 51–57
   PubMed Web of Science ®Google Scholar
• Peichev M, Naiyer A J, Pereira D, Zhu Z, Lane W J, Williams M, Oz M C, Hicklin D J, Witte L, Moore M A, et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000; 95: 952–958
   PubMed Web of Science ®Google Scholar
• Zhou Y, McMaster M, Woo K, Janatpour M, Perry J, Karpanen T, Alitalo K, Damsky C, Fisher S J. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 2002; 160: 1405–1423
   PubMed Web of Science ®Google Scholar
• Clark D E, Smith S K, Sharkey A M, Charnock-Jones D S. Localization of VEGF and expression of its receptors flt and KDR in human placenta throughout pregnancy. Hum Reprod 1996; 11: 1090–1098
   PubMed Web of Science ®Google Scholar
• Helske S, Vuorela P, Carpen O, Hornig C, Weich H, Halmesmaki E. Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies. Mol Hum Reprod 2001; 7: 205–210
   PubMed Web of Science ®Google Scholar
• Rajakumar A, Brandon H M, Daftary A, Ness R, Conrad K P. Evidence for the functional activity of hypoxia-inducible transcription factors overexpressed in preeclamptic placentae. Placenta 2004; 25: 763–769
   PubMed Web of Science ®Google Scholar
• Shibuya M. Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): A dual regulator for angiogenesis. Angiogenesis 2006; 9: 225–230
   PubMedGoogle Scholar
• Giraudo E, Primo L, Audero E, Gerber H P, Koolwijk P, Soker S, Klagsbrun M, Ferrara N, Bussolino F. Tumor necrosis factor-alpha regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells. J Biol Chem 1998; 273: 22 128–22 135
   Google Scholar
• Shen B Q, Lee D Y, Gerber H P, Keyt B A, Ferrara N, Zioncheck T F. Homologous up-regulation of KDR/Flk-1 receptor expression by vascular endothelial growth factor in vitro. J Biol Chem 1998; 273: 29 979–29 985
   Google Scholar
• Gerber H P, Condorelli F, Park J, Ferrara N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem 1997; 272: 23 659–23 667
   Google Scholar
• Waltenberger J, Mayr U, Pentz S, Hombach V. Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia. Circulation 1996; 94: 1647–1654
   PubMed Web of Science ®Google Scholar
• Kremer C, Breier G, Risau W, Plate K H. Up-regulation of flk-1/vascular endothelial growth factor receptor 2 by its ligand in a cerebral slice culture system. Cancer Res 1997; 57: 3852–3859
   PubMed Web of Science ®Google Scholar
• Tuder R M, Flook B E, Voelkel N F. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest 1995; 95: 1798–1807
   PubMed Web of Science ®Google Scholar
• Elvert G, Kappel A, Heidenreich R, Englmeier U, Lanz S, Acker T, Rauter M, Plate K, Sieweke M, Breier G, et al. Cooperative interaction of hypoxia-inducible factor-2alpha (HIF-2alpha) and Ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (Flk-1). J Biol Chem 2003; 278: 7520–7530
   PubMed Web of Science ®Google Scholar
• Detmar M, Brown L F, Berse B, Jackman R W, Elicker B M, Dvorak H F, Claffey K P. Hypoxia regulates the expression of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptors in human skin. J Invest Dermatol 1997; 108: 263–268
   PubMed Web of Science ®Google Scholar
• Reuvekamp A, Velsing-Aarts F V, Poulina I E, Capello J J, Duits A J. Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre-eclampsia. Br J Obstet Gynaecol 1999; 106: 1019–1022
   PubMedGoogle Scholar
• Sugawara J, Mitsui-Saito M, Hayashi C, Hoshiai T, Senoo M, Chisaka H, Yaegashi N, Okamura K. Decrease and senescence of endothelial progenitor cells in patients with preeclampsia. J Clin Endocrinol Metab 2005; 90: 5329–5332
   PubMed Web of Science ®Google Scholar
• Khan S S, Solomon M A, McCoy J P, Jr. Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry. Cytometry B Clin Cytom 2005; 64: 1–8
   PubMed Web of Science ®Google Scholar
• Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Bohm M, Nickenig G. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353: 999–1007
   PubMed Web of Science ®Google Scholar
• Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104: 2673–2678
   PubMed Web of Science ®Google Scholar
• Zhang Y, Jing-Ying M, Almirez R, de Forest N, Schellenberger U, Pollit S, Karumanchi S A, Schreiner G, Protter A A, Li Z. Over expression of soluble fms-like tyrosine kinase-1 (sFLT-1) induced experimental preeclampsia in rats and attenuation of preeclamptic phenotype by recombinant vascular endothelial growth factor 121 (VEGF 121). J Soc Gynecol Investig 2006; 2: 287A
   Google Scholar